55 results about "Trypanosoma sp" patented technology

A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.

Molecular targets are identified in T. cruzi suitable for use in diagnosis of Chagas disease, drug development, and vaccines, including live vaccines.

It is intended to provide a method of diagnosing infection with Chagas disease by screening a trypanocidal drugs for Trypanosoma cruzi which is the pathogen of Chagas disease. Using a flavin protein TcOYE specific to Trypanosoma cruzi, a trypanocidal drugs effective against Trypanosoma cruzi is screened. Using the gene sequence of TcOYE and an antibody therefor, infection with Trypanosoma cruzi is diagnosed.

The present invention relates to a process for heterologous expression and large-scale production of functionally active enzyme trypanothione reductase of Leishmania donovani in prokaryotic system.

A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma Cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions that codifying one or more immunogenic polypeptides, or a monocomponent comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from Trypanosoma Cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.

The invention discloses application of a reagent combination for detecting pathogens in preparation of a kit for detecting the quality of a blood product. The pathogens are selected from a pathogen group consisting of HAV, HBV, HCV, HEV, TP, HIV1, HIV2, HTLV1, HTLV2, HBOV, TTV, HCMV, B19, DENV, ZIKV, WNV, babesia, trypanosoma krusei and plasmodium, and belongs to the field of medical examination.The invention further discloses a corresponding kit and a method for detecting the quality of the blood product. By means of the kit, the lowest detection limit of pathogens is 1.0 * 10 < 3 > copies/mL, the kit has good specificity and repeatability, and an important technology is provided for screening and evaluating blood transfusion transmitted pathogens.

The invention discloses a combination slow release preparation for prevention and cure of livestock helminth, acarid and protozoon diseases, and the process for preparation comprising the steps of, using closantel and beta-cyclodextrin as the principal raw materials, carrying out rationalized proportioning and certain technological conditions, dissolving the closantel in solvent, charging distilled water into the beta-cyclodextrin, grinding till pasty state, mixing the two, drying and disintegrating.

The present invention relates inter alia to attenuated live parasites of the phylum Apicomplexa and the family of Trypanosomatdae and to the use of such attenuated live parasites in a vaccine and in the manufacturing of such a vaccine. Furthermore, the present invention relates to vaccines comprising such attenuated live parasites and to methods for the production of such vaccines. Finally, the invention relates to specific tet-repressor fusion proteins and to attenuated live parasites according to the invention comprising such tet-repressor fusion proteins.

The invention provides specific primers for the detection of Trypanosoma cruzi with the sequences as shown in SEQ ID No.1 and SEQ ID No.2, provides specific primers for the detection of Trypanosoma brucei with the sequences as shown in SEQ ID No.3 and SEQ ID No.4, provides specific primers for the detection of Trypanosoma brucei rhodesiense with the sequences as shown in SEQ ID No.5 and SEQ ID No.6, provides specific primers for the detection of Trypanosoma brucei gambiense with the sequences as shown in SEQ ID No.7 and SEQ ID No.8, provides a probe for the detection of Trypanosoma with the sequences as shown in SEQ ID No.9 to 26, and also provides a kit and a chip for the detection of Trypanosoma. In the invention, differential diagnosis for Trypanosoma infection can be specifically carried out.

The invention relates to a parasite quick detection technology in the technical field of biology, and discloses a specific primer in LAMP (looped-mediated isothermal amplification) detection of trypanosoma evansi variant strain with deletion of a ToTat1.2 gene. The specific primer comprises two pairs of LAMP primers FIP, BIP, F3 and B3 for detecting trypanosoma evansi. An LAMP method using the two pairs of primers to detect the trypanosoma evansi comprises the following steps of preparation of a reaction template, using of an LAMP reaction system and an LAMP reaction procedure, and judgment of detection results. The specific primer has the advantages that the operation is simple and convenient, the cost is low, the result is easily observed, and the specific primer is special for the detection of the trypanosoma evansi variant strain with deletion of the ToTat1.2 gene.

Novel dicationic bichalcophene compounds of formula (I) are described. The presently disclosed novel dicationic bichalcophene compounds exhibit in vitro activity versus Trypanosoma brucei rhodesiense, Plasmodium falciparum, or Leishmania donovani comparable to that of pentamidine and furamidine. Some of the novel dicationic bichalcophene compounds displayed good activity in vivo in a murine model of a Trypanosoma brucei rhodesiense infection.

The invention discloses a specific primer for detecting trypanosome protozoan. The sequences of the specific primer are as follows: the sequence of an upstream primer is 5'-CCTGATGAAAGGTGCAATG (SEQ IDNO: 1) or a complementary sequence thereof; the sequence of a downstream primer is 5'-CGTTTTCGCCTTCTTGTGGA (SEQ ID NO: 2) or a complementary sequence thereof. The invention further discloses a methodfor detecting the specificity of trypanosome protozoan. The method comprises the following steps: (1), extracting genome DNA of a target sample; (2), taking the extracted genome DNA of the target sample in the step (1) as a template, and performing PCR amplification through the specific primer; (3), performing agarose gel electrophoresis experiment on a PCR product, and observing whether a specific band exists in a target position. The specific primer and the detection method can rapidly and accurately detect whether trypanosome protozoan is contained in the target sample, the detection method is high in species universality, and strong in intergeneric specificity, and can specially perform effective detection on trypanosome protozoan. The invention further provides application of the primer.

The invention relates to the technical field of molecular biological detection, and provides a reagent and kit for isothermal amplification detection of trypanosoma buchneri species and trypanosoma buchneri subspecies (trypanosoma gambiense and trypanosoma rhodesiense) and application thereof. The reagent comprises the following loop-mediated isothermal nucleic acid amplification primer groups with SEQ ID No.1-SEQ ID No.18 for detecting the trypanosoma buchneri species and the trypanosoma buchneri subspecies (the trypanosoma gambiense and the trypanosoma rhodesiense), the reagent is high in sensitivity, good in repeatability, low in false negative and false positive and high in detection accuracy when used for detecting the trypanosoma buchneri species and the trypanosoma buchneri subspecies (the trypanosoma gambiense and the trypanosoma rhodesiense), and direct result judgment can be realized by observing color changes with the naked eyes.

The invention relates to a trypanosomalvaccine, to pharmaceutical compositions comprising said vaccine and to their uses in vaccination to prevent trypanosomal infection in a mammal.